Characterization of 5-fluorouracil microspheres for colonic delivery

AAPS PharmSciTech

Volumn 7, Issue 2, 2006, Pages

  Rahman, Ziyaur ^a   Kohli, Kanchan ^a   Khar, Roop K ^a   Ali, Mushir ^b   Charoo, Naseem A ^a   Shamsher, Areeg A A ^a  

^a HAMDARD UNIVERSITY   (India)

^b NONE   (India)

Author keywords

5 FU; Alginate; Colon specific; DSC; Eudragit S 100; HPLC; Microspheres

Indexed keywords

ALGINIC ACID; CALCIUM CHLORIDE; EUDRAGIT; FLUOROURACIL; LIQUID PARAFFIN; MICROSPHERE; SOLVENT; ANTINEOPLASTIC AGENT; DRUG VEHICLE;

ARTICLE; COLON CANCER; CONTROLLED STUDY; CROSS LINKING; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ANALYSIS; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STORAGE; DRUG SYNTHESIS; EMULSION; EVAPORATION; GASTROINTESTINAL TRACT; HUMIDITY; IN VITRO STUDY; PARTICLE SIZE; PH MEASUREMENT; SMALL INTESTINE; STOMACH; SUSTAINED DRUG RELEASE; THERMOGRAPHY; CHEMISTRY; COLON; COLON TUMOR; DELAYED RELEASE FORMULATION; DRUG SCREENING; ENTERIC COATED TABLET; EVALUATION; HUMAN; MATERIALS TESTING; STOMACH JUICE; VEHICLES;

ANTINEOPLASTIC AGENTS; COLON; COLONIC NEOPLASMS; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; FLUOROURACIL; GASTROINTESTINAL CONTENTS; HUMANS; MATERIALS TESTING; MICROSPHERES; PARTICLE SIZE; TABLETS, ENTERIC-COATED; VEHICLES;

EID: 33744899357     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070231     Document Type: Article

References (28)

1. Heidelberger C, Chaudhuri NK, Danneburg P, et al. Fluorinated pyrimidine. A new class of tumor inhibitory compounds. Nature. 1957;179:663-666.
2. Langenbach RJ, Dancenberg PV, Heidelberger C. Thymidylate synthetase: mechanism of inhibition of 5-fluorouracil-2-deoxyuridylate. Biochem Biophys Res Commun. 1972;48:1565-1571.
3. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381-395.
4. Hahn RG, Moertel CG, Schutt AJ, Bruckner HW. A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. Cancer. 1975;35:1031-1035.
5. Liu G, Fraussen E, Fitch MI, Warner E. Patient preferences for oral vs intravenous palliative chemotherapy. J Clin Oncol. 1997;15: 110-115.
6. Van Cutsem E, Peeters M, Verslype C, Filez L, Haustermans K, Janssens J. The medical treatment of colorectal cancer: actual status and new developments. Hepatogastroenterology. 1999;46:709-716.
7. Labianca RF, Beretta GD, Pessi MA. Disease management consideration. Drugs. 2001;61:1751-1764.
8. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215-237.
9. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm. 2002;235:1-15.
10. Shun YL, Ayres JW. Calcium alginate beads as core carriers of 5-aminosalicylic acid. Pharm Res. 1992;9:714-790.
11. Krishnaiah YSR, Satyanarayana V, Kumar DB, Karthikeyan RS, Bhaskar P. In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. Eur J Pharm Sci. 2003;19:355-362.
12. Madajewicz S, Petrelli N, Rustum YM, et. al. Phase I-II trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res. 1984;44:4667-4669.
13. Cortesi E, Aschelter AM, Gioacchini N, et al. Efficiency and toxicity of 5-fluorouracil and folates in advanced colon cancer. J Chemother. 1990;2:47-50.
14. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246-250.
15. Watts PJ, Barrow L, Steed KP, et al. The transit rate of different-sized model dosage forms through the human colon and effects of a lactulose induced catharsis. Int J Pharm. 1992;87: 215-221.
16. Calis S, Arica B, Kas HS, Hincal AA. 5-Fluorouracil-loaded alginate microspheres in chitosan gel for local therapy of breast cancer. In: Muzzarelli RAA, Muzzarelli C, eds. Chitosan in Pharmacy and Chemistry. Grottammare, Italy: Atec; 2002:65-69.
17. Lorenzo-Lamosa ML, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release. 1998;52:109-118.
18. Martel P, Petit I, Pinguet S, Poujol S, Astre C, Fabbro M. Long term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. J Pharm Biomed Anal. 1996;14:395-399.
19. Matthews BR. Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm. 1999;25:831-856.
20. Lin S, Kao Y. Solid particulates of drug-β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique. Int J Pharm. 1989;56:249-259.
21. Lemoine D, Wauters F, Bouchend S, Preat V. Preparation and characterization of alginate microspheres containing model antigen. Int J Pharm. 1998;176:9-19.
22. Wagner JG. Interpretation of percent dissolved-time plots derived from in-vitro testing of conventional tablets and capsules. J Pharm Sci. 1969;58:1253-1257.
23. Higuchi T. Mechanism of sustained action medication. J Pharm Sci. 1963;52:1145-1149.
24. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25-35.
25. Dubernet C. Thermo analysis of microspheres. Thermochim Acta. 1995;248:259-269.
26. Mu L, Feng SS. Fabrication characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Release. 2001;76:239-254.
27. Costa P, Labo JSMS. Modelling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-133.
28. Food and Drug Administration. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms; 1997. Rockville, MD.